http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103588754-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d890ad239375a780e6827d3407f15ef3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
filingDate 2013-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2015-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_794f6500f520625867d9e517a170c326
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75c2b864db3dc3294cf25df7e3d44b32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9814e8948c44f2aa0211f990d03d75f
publicationDate 2015-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103588754-B
titleOfInvention Preparation method of imatinib
abstract The invention relates to a preparation method of imatinib (I). Specifically, after a 6-methyl-N-(4-(pyridin-3-yl)pyrimidin-2-yl)-1,3-phenylenediamine reaction substrate (II) or a salt thereof is subjected to a reaction with p-halogenated methylbenzoyl halide in an inert solvent and in the presence of an alkali, any separation and purification treatment of an intermediate are not required, an in situ reaction with 1-methyl piperazine is directly carried out, and then the imatinib (I) target compound is obtained.
priorityDate 2013-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103145693-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6233
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424599094
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6344
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8028
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22292735
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412216270
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474137
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID634876
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86738798
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9965429
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414859102
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448098817
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11430
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID406885135
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3016395
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123596
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448020525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416219091
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456922693
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537701
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53167
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454269980
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID679
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534036
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411471142
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449702072
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559283
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID943
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538066

Total number of triples: 56.